Madera BioSciences

Mission: Madera BioSciences seeks to develop innovative therapeutics to up-regulate Apolipoprotein E (ApoE) expression for Alzheimer’s disease through collaboration with academia and the pharmaceutical industry. 

Madera is prosecuting small molecule programs seeking to decrease the burden of beta amyloid (Aβ) in Alzheimer’s disease. Specifically, we are currently developing drug-like molecules to increase the clearance of Aβ from the CNS. In addition, drugs that improve clearance of Aβ have therapeutic application in traumatic brain injury (TBI) and in age-related macular degeneration (AMD).